查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878915

非何杰金氏淋巴瘤治療市場：依療法類型、細胞類型、藥物類型、配銷通路與地區分類，競爭預測及機會（2020-2030 年預測）

Non-Hodgkin Lymphoma Therapeutics Market By Type of Therapy, By Cell Type, By Drug Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球非何杰金氏淋巴瘤（NHL）治療市場規模為81.9億美元，預計2030年將以7.61%的複合年成長率成長至127.2億美元。非何杰金氏淋巴瘤（NHL）治療涵蓋一系列旨在控制和對抗這類起源於淋巴系統的血液癌症的醫療手段。這些療法包括化療、標靶治療、免疫療法、放射療法和幹細胞移植，其目標是清除癌細胞並改善患者預後。

市場概覽
預測期 2026-2030
2024年市場規模 81.9億美元
2030年市場規模 127.2億美元
2025-2030年複合年成長率 7.61%
成長最快的細分市場 化療
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球非何杰金氏淋巴瘤（NHL）治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療類型（免疫療法、標靶治療、化療、幹細胞移植、其他）
    • 依細胞類型（B細胞淋巴瘤、T細胞淋巴瘤）
    • 依藥物類型（Revlimid、Rituxan、Keytruda、Imbruvica、Opdivo 等）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美非何杰金氏淋巴瘤（NHL）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲非何杰金氏淋巴瘤（NHL）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區非何杰金氏淋巴瘤（NHL）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲非何杰金氏淋巴瘤（NHL）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲非何杰金氏淋巴瘤（NHL）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球非何杰金氏淋巴瘤（NHL）治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Novartis AG
  • Eli Lilly and Company.
  • Spectrum Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol Myers Squibb Company
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 5113

The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market , valued at USD 8.19 Billion in 2024, is projected to experience a CAGR of 7.61% to reach USD 12.72 Billion by 2030. Non-Hodgkin Lymphoma (NHL) therapeutics comprise a range of medical treatments designed to manage and combat this diverse group of blood cancers originating within the lymphatic system. These therapies, encompassing chemotherapy, targeted therapy, immunotherapy, radiation, and stem cell transplantation, aim to eliminate malignant cells and improve patient outcomes.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 8.19 Billion
Market Size 2030USD 12.72 Billion
CAGR 2025-20307.61%
Fastest Growing SegmentChemotherapy
Largest MarketNorth America

Key Market Drivers

Advancements in immunotherapy and CAR T-cell therapies are a primary driver for the Non-Hodgkin Lymphoma therapeutics market, introducing highly effective and specialized treatments. These modalities utilize the patient's immune system or engineered immune cells to precisely target and eliminate cancer cells, offering transformative outcomes for aggressive or refractory NHL. Their increasing adoption, including expansion into earlier lines of treatment, significantly boosts market value. According to Gilead Sciences' full year 2024 financial results, released in February 2025, Cell Therapy product sales, encompassing NHL therapies like Yescarta, increased by 6% to reach $2.0 billion in the full year 2024 compared to 2023, reflecting substantial commercial success and clinical integration.

Key Market Challenges

The high cost associated with advanced therapeutic modalities presents a significant impediment to the growth of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market. Modern treatments, particularly immunotherapies, often feature substantial price tags. This directly limits patient access to potentially life-saving or life-extending therapies, especially in healthcare systems with stringent budgetary controls or for individuals with inadequate insurance coverage. Even for patients with coverage, significant out-of-pocket expenses can lead to treatment delays or abandonment, compromising optimal patient outcomes.

Key Market Trends

A significant trend driving the Global Non-Hodgkin Lymphoma therapeutics market is the robust pipeline development and continuous launch of novel drugs. This trend signifies a broader expansion of therapeutic options beyond established categories, addressing diverse patient needs and resistance mechanisms. According to OncLive, almost 20 FDA approvals occurred in the hematology sphere in 2024, demonstrating consistent innovation across blood cancers. This influx of new treatments provides clinicians with more tools to manage the complex and varied subtypes of NHL, including those that are aggressive or refractory.

Key Market Players

  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Novartis AG
  • Eli Lilly and Company.
  • Spectrum Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol Myers Squibb Company
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Type of Therapy:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Stem Cell Transplant
  • Others

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Cell Type:

  • B-cell Lymphomas
  • T-cell Lymphomas

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Drug Type:

  • Revlimid
  • Rituxan
  • Keytruda
  • Imbruvica
  • Opdivo
  • Others

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market .

Available Customizations:

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others)
    • 5.2.2. By Cell Type (B-cell Lymphomas, T-cell Lymphomas)
    • 5.2.3. By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others)
    • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Therapy
    • 6.2.2. By Cell Type
    • 6.2.3. By Drug Type
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type of Therapy
        • 6.3.1.2.2. By Cell Type
        • 6.3.1.2.3. By Drug Type
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type of Therapy
        • 6.3.2.2.2. By Cell Type
        • 6.3.2.2.3. By Drug Type
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type of Therapy
        • 6.3.3.2.2. By Cell Type
        • 6.3.3.2.3. By Drug Type
        • 6.3.3.2.4. By Distribution Channel

7. Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Therapy
    • 7.2.2. By Cell Type
    • 7.2.3. By Drug Type
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type of Therapy
        • 7.3.1.2.2. By Cell Type
        • 7.3.1.2.3. By Drug Type
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type of Therapy
        • 7.3.2.2.2. By Cell Type
        • 7.3.2.2.3. By Drug Type
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type of Therapy
        • 7.3.3.2.2. By Cell Type
        • 7.3.3.2.3. By Drug Type
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type of Therapy
        • 7.3.4.2.2. By Cell Type
        • 7.3.4.2.3. By Drug Type
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type of Therapy
        • 7.3.5.2.2. By Cell Type
        • 7.3.5.2.3. By Drug Type
        • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Therapy
    • 8.2.2. By Cell Type
    • 8.2.3. By Drug Type
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type of Therapy
        • 8.3.1.2.2. By Cell Type
        • 8.3.1.2.3. By Drug Type
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type of Therapy
        • 8.3.2.2.2. By Cell Type
        • 8.3.2.2.3. By Drug Type
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type of Therapy
        • 8.3.3.2.2. By Cell Type
        • 8.3.3.2.3. By Drug Type
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type of Therapy
        • 8.3.4.2.2. By Cell Type
        • 8.3.4.2.3. By Drug Type
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type of Therapy
        • 8.3.5.2.2. By Cell Type
        • 8.3.5.2.3. By Drug Type
        • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Therapy
    • 9.2.2. By Cell Type
    • 9.2.3. By Drug Type
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type of Therapy
        • 9.3.1.2.2. By Cell Type
        • 9.3.1.2.3. By Drug Type
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type of Therapy
        • 9.3.2.2.2. By Cell Type
        • 9.3.2.2.3. By Drug Type
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type of Therapy
        • 9.3.3.2.2. By Cell Type
        • 9.3.3.2.3. By Drug Type
        • 9.3.3.2.4. By Distribution Channel

10. South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Therapy
    • 10.2.2. By Cell Type
    • 10.2.3. By Drug Type
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type of Therapy
        • 10.3.1.2.2. By Cell Type
        • 10.3.1.2.3. By Drug Type
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type of Therapy
        • 10.3.2.2.2. By Cell Type
        • 10.3.2.2.3. By Drug Type
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type of Therapy
        • 10.3.3.2.2. By Cell Type
        • 10.3.3.2.3. By Drug Type
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market : SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AstraZeneca PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Baxter International Inc.
  • 15.3. Bayer AG
  • 15.4. Novartis AG
  • 15.5. Eli Lilly and Company.
  • 15.6. Spectrum Pharmaceuticals, Inc.
  • 15.7. Teva Pharmaceutical Industries Ltd.
  • 15.8. Bristol Myers Squibb Company
  • 15.9. GlaxoSmithKline PLC
  • 15.10. Janssen Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer